Concord Biotech Limited (CONCORDBIO) reported revenue of ₹257 Cr and net profit of ₹57.70 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
CONCORDBIO fundamentals, Fundamental score 60/100
The statements below are read from Concord Biotech Limited’s filed results, 13 filed quarters and 7 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 1, 2026 · audited
Sales CAGR · 3Y+7.3%FY22 → FY25
Sales CAGR · 4Y+10.3%FY21 → FY25
PAT CAGR · 3Y+2.6%FY22 → FY25
PAT CAGR · 4Y+10.3%FY21 → FY25
Price · 1Y−15.1%EOD
Price CAGR · 3Y+12.7%EOD
Quarterly resultsConsolidated
₹ Cr
Jun2023
Sep2023
Dec2023
Mar2024
Jun2024
Sep2024
Dec2024
Mar2025
Jun2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
195
262
241
319
216
310
244
430
204
247
278
326
257
+26.2%
123
143
135
185
135
174
146
239
143
159
179
208
175
+22.8%
Operating profit
72.2
119
106
134
81.3
137
98.0
190
61.4
88.5
99.0
119
82.4
+34.2%
OPM %
37.0%
45.4%
44.0%
42.1%
37.7%
44.1%
40.1%
44.3%
30.1%
35.8%
35.6%
36.4%
32.0%
+1.9 pp
Other income
6.65
8.13
8.19
10.8
10.3
10.0
14.7
9.38
13.7
13.4
9.98
15.3
12.8
-6.2%
Interest
0.75
0.84
0.50
0.46
0.24
0.10
0.10
0.10
0.06
0.06
0.08
0.08
0.04
-37.9%
Depreciation
13.0
13.3
13.5
13.7
13.2
13.3
13.3
14.6
17.8
18.4
18.7
19.5
18.1
+1.8%
Profit before tax
65.0
113
100
131
78.2
133
99.3
185
57.2
83.4
86.9
114
77.1
+34.6%
Tax %
25.4%
25.3%
25.5%
25.7%
25.5%
26.0%
25.4%
23.3%
25.6%
27.1%
25.9%
22.4%
26.8%
+1.2 pp
Net profit
54.5
81.0
77.6
95.0
59.6
95.7
75.9
140
44.1
63.1
63.6
88.5
57.7
+31.0%
EPS (₹)
5.21
7.74
7.41
9.08
5.70
9.15
7.26
13.42
4.21
6.03
6.08
8.46
5.52
+31.1%
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Revenue & net profit trend
last 13 quarters
RevenueNet profit
Revenue & net profit — Consolidated13 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±3.9%· EPS surprise: no estimates source· 1 earlier quarter has no dated filing on record
